Published on
August 12, 2022

Psychedelic Weekly Headlines | August 12th

Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.


Markets

Performance of psychedelic public companies this past week.


Company News

Optimi Health ($OPTI | $OPTHF) partnered with psilocybin patient advocate, Thomas Hartle to produce a Canadian-grown and harvested natural therapeutic psilocybin product for use by approved patients. Press Release          

Lobe Sciences ($LOBE | $LOBEF) entered into an exclusive agreement with iNGENū Pty, an Australian based Contract Research Organization, to design and conduct clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131. Press Release          

PsyBio Therapeutics ($PSYB | $PSYBF) filed international patent applications in Europe, Africa, and Asia, bringing their total number of patent application submissions to twenty, further strengthening and expanding their IP portfolio. Press Release          

Field Trip Health ($FTRP) closed their spin-out transaction, splitting the company's drug development and clinical divisions, and completed a $19.9 million private placement. Field Trip will be renamed 'Reunion Neuroscience', with the ticker symbol changing to "REUN". Field Trip Health & Wellness Ltd. will be listed on the TSX Venture Exchange under ticker symbol “FTHW”. Press Release          

Irwin Naturals ($IWIN | $IWINF) completed the acquisition of two ketamine clinics in Georgia. The clinics offer ketamine-assisted therapy and hydration via IV infusion. Press Release          

Mind Medicine ($MNMD | $MMED) provided operational results. Highlights included a Phase IIb dose-optimization trial for MM-120 in patients with General Anxiety Disorder and advanced IND-enabling studies for MM-402 with the Phase I trial planned for Q3. Press Release          

Cybin ($CYBN) established an at-the-market equity program that allows Cybin to issue and sell up to USD$35,000,000 of common shares from the company treasury to the public. Press Release          

Revitalist Lifestyle And Wellness ($CALM | $RVLWF) reported continued expansion of service lines to generate new revenue streams, including a training program for practitioners seeking to advance competency in the psychedelic and ketamine wellness space. Press Release          


Media

USA Today: Psilocybin Therapy In States Helping Legalize Psychedelics in US          

Psychology Today: Could Psychedelic Medicine Help People Living With Memory Loss?          

Bloomberg: Psilocybin Legal in US, Canada? Lawsuit May Help          

The Independent: Over The Counter Culture: Are Psychedelics Coming To The Corner Shop?          


Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.